82413-23-8 Usage
Description
4’-hydroxy Tamoxifen is one of five main phase I metabolites of tamoxifen , a well-known estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium. 4’-hydroxy Tamoxifen is a product of cytochrome P450 (CYP)2D6 and CYP2B6 activity. With the addition of a hydroxyl group, 4’-hydroxy tamoxifen has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. At 10-100 μM, 4’-hydroxy tamoxifen is cytotoxic, in a non-apoptotic manner, to HEC-1B and HEC-1A human endometrial adenocarcinoma cell lines.
Chemical Properties
White Solid
Check Digit Verification of cas no
The CAS Registry Mumber 82413-23-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,4,1 and 3 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 82413-23:
(7*8)+(6*2)+(5*4)+(4*1)+(3*3)+(2*2)+(1*3)=108
108 % 10 = 8
So 82413-23-8 is a valid CAS Registry Number.
82413-23-8Relevant articles and documents
Synthesis of tetrasubstituted alkenes by stereo- and regioselective stannyllithiation of diarylacetylenes
Tsuji, Hayato,Ueda, Yasuyuki,Ilies, Laurean,Nakamura, Eiichi
supporting information; experimental part, p. 11854 - 11855 (2010/10/19)
Addition of trimethylstannyllithium to a diarylacetylene takes place exclusively in an anti-fashion to produce a lithio vinylstannane intermediate. The regioselectivity of the addition is controlled by the steric and electronic property of the acetylene and reaches up to >99:1. The two newly formed C-metal bonds can be sequentially and stereospecifically transformed into two new C-C bonds as illustrated by stereoselective synthesis of 4-hydroxytamoxifen and its regioisomer. A tetraarylethene bearing different aryl groups can be synthesized similarly and cyclized to a substituted dibenzo[g,p]chrysene derivative via a palladium-catalyzed arylation reaction.
